DFC Global Corp (NASDAQ:DLLR) up by 1.20, InterMune Inc (NASDAQ:ITMN)

Posted by George Brook May 16, 2013 0 Comment 1313 views


DFC Global Corp (NASDAQ:DLLR): In Wednesday’s trading session DFC Global Corp (NASDAQ:DLLR) climbed by 1.20%. It opened at a price of $14.90, touched an intraday high of $15.23, moving down to close at $15.17 per share. More than 0.290 million shares have exchanged hands in today’s trading session, which stands below the average volume of 0.565 million that is measured over a 30-day period.

DLLR was formerly known as Dollar Financial Corp. It is an international non-bank, alternative financial services provider. DFC Global Corp (NASDAQ:DLLR) provides secured pawn loans, unsecured short-term consumer loans, money transfers, check cashing as well as re-loadable prepaid debit cards. As of 2012 June, it served under-banked and un-banked consumers via its more than 1,400 retail storefront locations. It also has numerous Internet platforms across eight countries in the United States, Europe, Canada, the Finland, Sweden, Poland, Spain and the Republic of Ireland. The services and products it offers provide customers with access to cash for regular living expenses and any other needs. On 15 March 2012, DFC Global Corp (NASDAQ:DLLR) acquired Super Efectivo S.L. In 2012 November, DLLR acquired ten pawn-broking stores in the U.K

InterMune Inc (NASDAQ:ITMN): In Wednesday’s trading session InterMune Inc (NASDAQ:ITMN) dropped by 1.09%. It opened at a price of $10.32, touched an intraday high of $10.55, before moving down to close at $10.39 per share. More than 1.11 million shares exchanged hands in today’s trading session, which stands below the average volume of 1.50 million that is measured over a 30-day period.

ITMN is a biotech company that focuses on researching, developing and the commercialization of orphan fibrotic diseases and pulmonology therapies.  The latter is a field of medicine that is related to the diagnosis and treatment of different lung conditions. Pirfenidone is one of  InterMune Inc (NASDAQ:ITMN)’ pulmonology products. It is an orally-active, small molecule compound. On 2 January 2013, the company began launched Esbriet in Canada. On 19 June 2012, it completed the divestiture of its global development and its commercialization rights for Actimmune. This pharmaceutical product contains Interferon Gamma-1b. The rights for this particular product were sold to Vidara Therapeutics International Limited.


About George Brook

George Brook covers money and politics for GDP Insider. George is a veteran journalist who has also covered Congress, national political conventions and presidential politics. George also covers the White House as well as economic and domestic policy for GDP insider. George's reporting has won numerous awards, including two Scripps Howard awards, two National Headliners, two Gerald Loeb Awards, as well as honors from Sigma Delta Chi and the National Press Club.

View all post by George Brook Visit author's website

Write Your Comment